Krystal Biotech

@KrystalBiotech

Krystal Biotech, Inc. is using gene therapy to develop effective and novel treatments for skin diseases.

Vrijeme pridruživanja: veljača 2018.

Tweetovi

Blokirali ste korisnika/cu @KrystalBiotech

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @KrystalBiotech

  1. 27. sij

    We broke ground on a second cGMP facility for our treatments for skin conditions. The Astra facility is intended to support potential commercial production of B-VEC, formerly KB103, as well as ongoing R&D efforts. Full details here:

    Poništi
  2. 23. sij

    We are pleased to announce the strengthening of our team with Jennifer Chien joining the newly created CCO position. Ms. Chien brings more than 20 years commercial leadership experience that is critical as we look towards potential launch of KB103 in 2021:

    Poništi
  3. 27. stu 2019.

    Today's article from and highlights as one of 11 companies leading the way by making early investments in manufacturing, greatly streamlining the therapy development process. Read it here:

    Poništi
  4. 26. stu 2019.

    CEO Krish S. Krishnan will be presenting a corporate update at the upcoming Piper Jaffray 31st Annual Healthcare Conference in New York on Tuesday December 3 at 9:10 a.m. ET. Webcast link for the presentation can be found here:

    Poništi
  5. 5. stu 2019.

    We published a corporate update and third quarter 2019 financial results. Click here to see the full release: and check for additional info.

    Poništi
  6. 29. lis 2019.

    In the final data update from the Phase 1/2 trial of KB103, now B-VEC, the topical induced rapid and durable wound closure in patients with dystrophic and was safe and well-tolerated. Read the full release here:

    Poništi
  7. 16. lis 2019.

    We reinforced our IP portfolio with (1) a US patent for our platform technology, and (2) the first foreign patent (Australia) for our lead product KB103. We remain committed to developing novel therapeutics for rare skin diseases. Full release

    Poništi
  8. 10. lis 2019.

    The EMA Committee for Orphan Medicinal Products issued a positive opinion on our orphan designation application for KB105, our second treatment, for patients with transglutaminase-1 deficient autosomal recessive congenital ichthyosis:

    Poništi
  9. 9. ruj 2019.

    A new was just initiated and will study topical KB105 for treatment of transglutaminase-1 (TGM1) deficient autosomal recessive congenital (ARCI). Read more about the trial here:

    Poništi
  10. 3. ruj 2019.

    CEO Krish Krishnan shares his advice with on raising capital in and on how previous success in the industry paved the way for an initially self-funded company and a rapid IPO. Read the full story here:

    Poništi
  11. 20. kol 2019.

    KB103 study coordinator Dr. Peter Marinkovich was featured in speaking about trial results, future plans and the hope this developmental could give to all those affected by dystrophic . Read it here:

    Poništi
  12. 5. kol 2019.

    Krystal reports second quarter 2019 financial results including recent milestones and program updates. Full release here:

    Poništi
  13. 24. lip 2019.

    Data from the Phase 2 GEM2 study show that KB103 was well-tolerated and induced rapid & durable wound closure in adult & pediatric patients with dystrophic . Granted RMAT designation paves way for a planned pivotal Phase 3 before 2020.

    Poništi
  14. 14. lip 2019.

    We submitted an IND for a new candidate, KB105, for patients with the TGM-1 deficient autosomal recessive congenital ichthyosis (“ARCI”). Read the full release here:

    Poništi
  15. 29. ožu 2019.

    KB103, our clinical-stage first-in-class topical for the treatment of dystrophic , was granted PRIME eligibility by , allowing for frequent and early interactions with the EMA to accelerate development:

    Poništi
  16. proslijedio/la je Tweet

    . is currently recruiting patients onto their Phase 2 Study of KB103 (The GEM Study). KB103 is a topical gene therapy being evaluated in RDEB patients. For more information, please visit:

    Poništi
  17. 6. ožu 2019.

    We celebrated the opening of Ancoris, our GMP facility for all production needs for KB103, our developmental treatment for dystrophic . We were honored to be joined by :

    Poništi
  18. 4. ožu 2019.

    Join us in welcoming the newest member of our Board of Directors, Julian S Gangolli, whose vast experience with product launches will be invaluable as we progress our lead developmental product KB103 towards commercialization. For more details, see here:

    Poništi
  19. 12. velj 2019.

    A new article from highlights Ancoris, our state-of-the-art GMP facility designed to meet expected current and future research and production needs for lead developmental KB103, for . Read the story here:

    Poništi
  20. 16. sij 2019.

    Our new state-of-the-art GMP facility, Ancoris, set to be the primary production site to meet projected research and commercial demand for KB103, was just completed. We're already planning a second facility to meet all future needs. Full news release here:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·